CYCC - Cyclacel Pharmaceuticals GAAP EPS of -$0.60 misses by $0.12

2023-03-06 16:20:30 ET

• Cyclacel Pharmaceuticals press release ( NASDAQ: CYCC ): Q4 GAAP EPS of -$0.60 misses by $0.12 .
• Report final data from dose escalation stage and RP2D determination from the 065-101 study of oral fadraciclib in patients with advanced solid tumors and lymphoma
• First patient dosed with oral fadraciclib in Phase 2 proof-of-concept stage of 065-101 study in patients with advanced solid tumors and lymphoma
• Report interim Phase 1 data from 140-101 study of oral plogosertib in patients with advanced solid tumors and lymphoma
• Report interim data from initial cohorts in Phase 2 proof-of-concept stage of 065-101 study with oral fadraciclib in patients with advanced solid tumors and lymphoma
• Report interim data from dose escalation stage of 065-102 study with oral fadraciclib in patients with advanced leukemia
• Report final data from dose escalation stage of 140-101 study with oral plogosertib in advanced solid tumors and lymphoma.
• As of December 31, 2022, cash and cash equivalents totaled $18.3 million, compared to $36.6 million as of December 31, 2021.

For further details see: